ABD-3001

Phase 2Small molecule

AAdvanced BioDesign

ABD-3001 is one of 4 small molecule programs targeting Relapsed AML. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed AMLRecruiting

Relapsed AMLPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Relapsed AML

#DrugCompanyPhaseTrials

Ayvakit

BBlueprint Medicines

Phase 2

1 2

Liposome-Encapsulated Daunorubicin-Cytarabine

MM.D. Anderson Cancer Center

Phase 2

1 3

Enasidenib Mesylate

CChildren's Oncology Group

Phase 2

1 4

ABD-3001

AAdvanced BioDesign

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Relapsed AML

NCT05601726

Clinical

Trials by Indication[1]

Relapsed AML1 trial

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Recruiting·AAdvanced BioDesign·Phase 1/2·NCT05601726·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABD-3001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABD-3001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABD-3001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advanced BioDesign company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAdvanced BioDesign

ABD-3001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Relapsed AML1 trial

References

Drug Info

Quick Facts

Related News